Sodium bicarbonate treatment and clinical outcomes in chronic kidney disease with metabolic acidosis: a meta-analysis

Author:

Yang Ting-Ya1ORCID,Lin Hong-Min1ORCID,Wang Hsien-Yi23,Chuang Min-Hsiang2ORCID,Hsieh Chia-Chen1,Tsai Kang-Ting14,Chen Jui-Yi25ORCID

Affiliation:

1. Department of Family Medicine, Chi Mei Medical Center, Tainan, Taiwan

2. Division of Nephrology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan

3. Department of Sport Management, College of Leisure and Recreation Management, Chia Nan University of Pharmacy and Science, Tainan, Taiwan

4. Department of Senior Welfare and Services, College of Humanities and Social Science, Southern Taiwan University of Science and Technology

5. Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.

Abstract

Background: In patients with chronic kidney disease (CKD), impaired kidney acid excretion leads to the onset of metabolic acidosis (MA). However, the evidence is not yet conclusive regarding the effects of sodium bicarbonate in treating CKD with MA. Methods: Databases with PubMed, Embase, and the Cochrane Library were used to search for randomized controlled trials from the inception until November 11, 2023 to identify randomized controlled trials investigating the effect of sodium bicarbonate in participants with CKD and MA. The primary outcome was the change in estimated glomerular filtration rate (eGFR). Secondary outcomes included hospitalization rates, change in systolic blood pressure (SBP), all-cause mortality, and mid-arm muscle circumference (MAMC). A random-effects model was applied for analysis, and subgroup, sensitivity analyses were also performed. Results: Fourteen RCTs comprising 2,037 patients demonstrated that sodium bicarbonate supplementation significantly improved eGFR (standardized mean difference [SMD]: 0.33, 95% CI: 0.03 to 0.63, P = 0.03). The group receiving sodium bicarbonate had a lower hospitalization rate (odds ratio: 0.37, 95% CI: 0.25 to 0.55, P < 0.001). Higher MAMC was observed with sodium bicarbonate treatment compared with those without (SMD:0.23, 95% CI: 0.08 to 0.38, P = 0.003, I2 < 0.001). However, higher risk of elevated SBP was found with sodium bicarbonate treatment (SMD:0.10, 95% CI: 0.01 to 0.20, P = 0.03). No significant difference in all-cause mortality was noted. Conclusion: In patients with CKD and MA, sodium bicarbonate supplementation may provide potential benefits in preventing the deterioration of kidney function and increasing muscle mass. However, treatment may be associated with higher blood pressure. Due to the risk of bias stemming from the absence of double-blinded designs and inconsistencies in control group definitions across the studies, further research is crucial to verify these findings.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference47 articles.

1. Acid-base homeostasis;Hamm;Clin J Am Soc Nephrol.,2015

2. Metabolic acidosis in CKD: core curriculum 2019;Raphael;Am J Kidney Dis.,2019

3. The kidney disease: improving global outcomes (KDIGO) Chapter 3: Management of progression and complications of CKD;Kidney Int. Suppl,2013

4. Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial;Dubey;Nephrol Dial Transplant.,2020

5. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study;Di Iorio;J Nephrol.,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3